 |
|
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
Korean J Intern Med. 2019;34(4):794-801. Published online 2018 May 25 DOI: https://doi.org/10.3904/kjim.2017.368
|
|
Citations to this article as recorded by
 Opportunities and challenges for the application of artificial intelligence paradigms into the management of endemic viral infections: The example of Chronic Hepatitis C Virus
Ahmed N. Farrag, Ahmed M. Kamel, Iman A. ElâBaraky
Reviews in Medical Virology.2024;[Epub] CrossRef Effectiveness of Ledipasvir-Sofosbuvir 12 Weeks After Hepatitis C Virus Genotype 1 Infection and the Factors Associated With Sustained Virologic Response: A Retrospective Study
Ismaeel A Alshoaibi, Abdullah Al-Gamli, Mohammed Abdullah, Basheer Abdo, Khaled H Alzanen, Mohammed Alhakamy, Mamoon Al-Namer, Faisal Ahmed, Munther Tamesh , Wadhah Mahdi , Zeyad Abdo, Marwa Mohammed
Cureus.2024;[Epub] CrossRef Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation
Nirmeen Sabry, Ahmed M. Kamel, Ahmed Cordie, Gamal Esmat
Expert Opinion on Pharmacotherapy.2023; 24(2): 159. CrossRef Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
Jae-Hyun Yoon, Sung-Eun Kim, Su-Hyeon Cho, Gi-Ae Kim, Yewan Park, Ji-Won Park, Seong-Hee Kang, Young-Sun Lee, Jeong-Han Kim
Medicina.2023; 59(8): 1436. CrossRef Current therapeutics against HCV
Chayan Bhattacharjee, Maitri Singh, Debisukti Das, Sujit Chaudhuri, Aparna Mukhopadhyay
VirusDisease.2021; 32(2): 228. CrossRef Asunaprevir/daclatasvir
Reactions Weekly.2019; 1770(1): 61. CrossRef
|